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Background: The objective of the present population-based analysis was to assess survival patterns in patients with
resected and metastatic GIST.
Methods: Patients with histologically proven GIST were extracted from the Surveillance, Epidemiology and End
Results (SEER) database from 1998 through 2011. Survival was determined applying Kaplan-Meier-estimates and
multivariable Cox-regression analyses. The impact of size and mitotic count on survival was assessed with a
generalized receiver-operating characteristic-analysis.
Results: Overall, 5138 patients were included. Median age was 62 years (range: 18–101 years), 47.3 % were female,
68.8 % Caucasians. GIST location was in the stomach in 58.7 % and small bowel in 31.2 %. Lymph node and distant
metastases were found in 5.1 and 18.0 %, respectively. For non-metastatic GIST, three-year overall survival increased
from 68.5 % (95 % CI: 58.8–79.8 %) in 1998 to 88.6 % (95 % CI: 85.3–92.0 %) in 2008, cancer-specific survival from 75.3 %
(95 % CI: 66.1–85.9 %) in 1998 to 92.2 % (95 % CI: 89.4–95.1 %) in 2008. For metastatic GIST, three-year overall survival
increased from 15.0 % (95 % CI: 5.3–42.6 %) in 1998 to 54.7 % (95 % CI: 44.4–67.3 %) in 2008, cancer-specific survival
from 15.0 % (95 % CI: 5.3–42.6 %) in 1998 to 61.9 % (95 % CI: 51.4–74.5 %) in 2008 (all PTrend < 0.05).
Conclusions: This is the first SEER trend analysis assessing outcomes in a large cohort of GIST patients over a
11-year time period. The analysis provides compelling evidence of a statistically significant and clinically relevant
increase in overall and cancer-specific survival from 1998 to 2008, both for resected as well as metastatic GIST.
Keywords: Gastrointestinal stromal tumors (GIST), Surveillance, Epidemiology and End Results (SEER) database, Trend
analysis, Gastric GISTBackground
Gastrointestinal stromal tumors (GIST) are the most fre-
quent mesenchymal malignancies of the gastro-intestinal
tract. The origin of GIST is the cell of Cajal, which is
the pace-maker cell located between the circular and
longitudinal muscle layer along the gastro-intestinal
tract and is responsible for the gastro-intestinal motility.
GIST occur most frequently in the stomach and small
bowel, other locations such as esophagus, colon, rectum
and extravisceral locations are rare.* Correspondence: Ulrich.Gueller@kssg.ch
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creativecommons.org/publicdomain/zero/1.0/For many decades surgery was the only efficient treat-
ment modality for GIST. However, despite complete re-
section, the high recurrence rate remained an unsettling
problem. The use of chemotherapy or radiation was
proven to be largely ineffective [1]. However, over the
past 15 years substantial improvements were made in
the understanding of the pathogenesis and treatment of
GIST. Around the change of millennium physicians
began to understand that GIST are a result of a KIT or
PDGFR mutation and more importantly, that the result-
ing mutated KIT or PDGF receptor could be blocked by
the tyrosine kinase inhibitor imatinib. This targeted
agent, which previously had a tremendous success in
treating chronic myeloid leukemia by blocking the ABL-
kinase of the BCR-ABL fusion protein, was now alsoicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Fig. 1 Patient selection
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in a female patient with a metastatic GIST, who was un-
successfully treated with different chemotherapies [2].
After 4 weeks of imatinib treatment, a phenomenal re-
sponse was seen on PET scan. Since then, many studies
including several randomized trials have been performed
using imatinib in non-metastatic [3, 4] and metastatic
GIST [5, 6].
However, it remains unknown whether improvements
in understanding and management of GIST patients have
resulted in relevant patient benefits on a population-based
level. Therefore, the primary objective of the present ana-
lysis was to assess whether overall and cancer-specific sur-
vival of GIST patients have improved over a 11-year time
period.
Methods
Cohort definition
The recent ASCII text data-version of the Surveillance,
Epidemiology, and End Results (SEER) Program of the
National Cancer Institute in the United States, covering
approximately 28 % of cancer cases in the United States,
was the source of present population-based analysis [7].
SEER data were collected and reported using data items
and codes as documented by the North American Asso-
ciation of Central Cancer Registries (NAACCR) [8]. Pri-
mary cancer site and histology were coded according to
criteria in the third edition of the International Classifi-
cation of Diseases for Oncology (ICD-O-3) [9].
GIST patients were identified by the primary sites
esophagus, stomach, small intestine, colon, rectum, ap-
pendix, peritoneum and the codes “8935” and “8936” for
ICD-O-3 histology. Patients diagnosed at autopsy or by
death certificate only as well as patients without histo-
logical confirmation were excluded (NAACCR Items 490
and 2180). Patients with other SEER reportable cancers
were excluded unless the GIST was the first diagnosed
malignancy (NAACCR Item 380) in order to use the
cancer-specific survival. Patients with pediatric GIST (n =
24) were excluded from the analysis (Fig. 1). Size was
coded as a continuous variable in mm. Five patients with
GIST sizes exceeding 70 cm were excluded from analyses
involving GIST size.
Statistical analysis
Statistical analyses were performed using the R
statistical software (www.r-project.org). A two-sided
p-value < 0.05 was considered statistically significant.
Continuous data are expressed as median and inter-
quartile range (IQR). After descriptive analysis, sur-
vival was assessed by Kaplan-Meier analysis. Overall
and cancer-specific survival were the designated end-
points. For analysis of overall survival, the time from
diagnosis until the end of the follow-up was usedtogether with the information whether a patient died
or not. For cancer-specific survival, cancer-associated
deaths were counted for the estimation of the cancer-
specific survival whereas other deaths unrelated to
GIST were censored. The censoring was based on the
coding of these endpoints in the SEER database (alive,
cancer-associated death, other death). P-values were
computed using Cox-regression and likelihood-ratio-
tests. To assess the association between GIST size
and survival, locally weighted scatterplot smoothing
(LOWESS)-Regression was performed [10]. To analyze
the predictive value of the continuous variables size
and mitotic rate for survival, a generalized receiver-
operating characteristic (ROC)-methodology for
survival analysis was applied [11]. Sensitivity and 1-
specificity for prediction of one-year survival were
simultaneously plotted as ROC-curves and the area
under the curve (AUC) was estimated. Mitotic count
was systematically recorded after 2009, therefore only
one year survival rates were computable. For each
distinct value of mitotic count and size, the pairs of
‘true positives’ (number of patients for whom death
was predicted and who died) and ‘false positives’
(number of patients for whom death was predicted
and who survived) are displayed [11]. These pairs
form the receiver-operating characteristic (ROC)-
curve. The area under the curve (AUC) of a perfect
predictor would have an AUC of 1 and the ROC-
curve would have an ROC plot along the left side
Table 1 Patients’ characteristics
Variable Category All GIST
(N = 5138)
Location Stomach 3018 (58.7 %)
Small intestine 1603 (31.2 %)
Other: 517 (10.1 %)
• Esophageal 29 (0.6 %)
• Colon 139 (2.7 %)
• Rectum 172 (3.3 %)
• Appendix 3 (0.1 %)
• Peritoneum 174 (3.4 %)
Size categories <5 cm 1280 (24.9 %)
5 cm–9.9 cm 1678 (32.7 %)
10 cm+ 1471 (28.6 %)
Unknown 709 (13.8 %)
Size (cm) Median [IQR] 7.0 cm [4.5 to
11.8 cm]
Range 0.2–70 cm
N stage N− 4071 (79.2 %)
N+ 264 (5.1 %)
NX 803 (15.6 %)
Mitotic Counta <2 per 50 HPF 397 (7.7 %)
2–5 per 50 HPF 171 (3.3 %)
>5 per 50 HPF 159 (3.1 %)
Unknown 4411 (85.9 %)
Surgery of
primary
No surgery of primary tumor 865 (16.8 %)
Surgery of primary tumor 4263 (83.0 %)
Unknown 10 (0.2 %)
Metastatic disease M0 4211 (82.0 %)
M1: 927 (18.0 %)
−M1, no surgery of
metastasis
−763 (14.8 %)
−M1, surgery of metastasis −139 (2.7 %)
−M1, surgery of metastasis −25 (0.5 %)
unknown
Year 1998 to 2002 1120 (21.8 %)
2003 to 2005 1195 (23.3 %)
2006 to 2008 1227 (23.9 %)
2009 to 2011 1596 (31.1 %)
Gender Male 2709 (52.7 %)
Female 2429 (47.3 %)
Age <50 1060 (20.6 %)
50–64 1805 (35.1 %)
65–79 1682 (32.7 %)
80+ 591 (11.5 %)
Ethnicity Caucasian 3536 (68.8 %)
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chance, the AUC is 0.5 and the ROC-curves are on
the diagonal line (“chance diagonal”) [12]. The statis-
tically optimal cut-off value was estimated by maxi-
mizing the Youden index (computed as Sensitivity +
Specificity-1). Multivariable survival analyses were
done using Cox regression analyses. The proportional
hazard assumption was tested by scaled Schoenfeld
residuals and by inspection of the hazard ratio (HR)
plots [13]. For trend analysis, Spearman’s rho was ap-
plied. Extrapolation of survival rates was based on the
covariate vector for the year of diagnosis modeled as
a factorial variable in Cox regression.
Ethics statement
This study was based on public use de-identified data
from the SEER database and did not involve interaction
with human subjects or use personal identifying infor-
mation. The study did not require informed consent
from the SEER registered cases and the authors obtained
Limited-Use Data Agreements from SEER.
Results
Patient characteristics
Overall 5138 patients diagnosed with GIST between
1998 and 2011 in one of the regions covered by SEER
were eligible for the present analysis (Fig. 1). The me-
dian follow-up in our patient cohort was 37 months
(interquartile range: 14 to 74 months). The median age
was 62 years (interquartile range 52 to 73 years) with a
range of 18 to 101 years, 47.3 % were female, 68.8 %
Caucasians. GISTs were located in the stomach in
58.7 % and small bowel in 31.2 %. All other locations
were rare (Table 1). Lymph node metastases were found
in 5.1 %, distant metastases in 18.0 % of all patients
(Table 1). Median size of the GIST was 7.0 cm (inter-
quartile range 4.5 to 11.8 cm) with a range from 0.2 to
70 cm.
Univariable survival analysis
At the end of follow-up 3545 (69.0 %) patients were alive,
1080 (21.0 %) died from GIST and 513 (10.0 %) died due
to reasons which were not associated with the GIST ac-
cording to the coding in the SEER database. In patients
with non-metastatic GIST lymph node metastases were
associated with a significantly decreased overall and
cancer-specific survival (P < 0.001, Fig. 2 panel a and b).
Overall and cancer-specific survival was significantly de-
creased in patients with metastatic GIST and further so in
patients without surgery of the primary tumor (P < 0.001,
Fig. 2 panel c and d). Larger tumors were associated with
significantly worse survival: Five-year overall survival rates
were 81, 80 and 65 % (P < 0.001) in GIST tumors <5 cm,
5–9.9 cm and = > 10 cm, respectively. Five-year cancer-
Table 1 Patients’ characteristics (Continued)
African-American 920 (17.9 %)
Other/Unknown 682 (13.3 %)
Marital status Married 3008 (58.5 %)
Single 832 (16.2 %)
Other/Unknown 1298 (25.3 %)
Cause of death Alive 3545 (69.0 %)
Dead from cancer 1080 (21.0 %)
Dead not from cancer 513 (10.0 %)
Follow-up
(months)
Median [IQR] 37.0 [14.0 to 74.0]
a Mitotic count systematically recorded after 2009
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ive size categories (P < 0.001, Fig. 2 panel e and f).
Tumor size and mitotic count
Figure 3 displays the GIST size (panel b) and its associ-
ation with overall and cancer-specific survival (panel a)
in patients with non-metastatic disease. The size distri-
bution peaks at 5 cm. For sizes exceeding 8 cm a marked
decrease in overall and cancer-specific survival was ob-
served for non-metastic GIST patients.
Figure 4 displays the predictive value of mitotic
count (panel a) and tumor size (panel b) for one-year
cancer-specific survival using the ROC-methodology.
The impact of size on survival is lower compared to
the mitotic count (area under the curve of 0.63 com-
pared to 0.77). The statistically optimal (defined as
maximal Youden index) cut-off value of mitotic count
was 5 in 50 high power fields (HPF). For GIST size,
the statistically optimal cut-off is 8 cm. Similar results
were obtained for overall survival (Fig. 5). The pre-
dictive value of mitotic count (panel a) was higher
than the predictive value of the tumor size (panel b).
The impact on overall survival was lower than on
cancer-specific survival considering the lower area
under the curve observed for mitotic count and for
tumor size.
Multivariable survival analysis
In multivariable analysis of overall survival GIST loca-
tion other than stomach and small bowel (hazard ratio
(HR) 1.30, P = 0.002), tumor size above 10 cm (HR 1.63;
P < 0.001), presence of distant (HR 2.03; P < 0.001) and
lymph node metastases (HR 1.47; P = 0.001), older age
(P < 0.001), single marital status (HR 1.38; P < 0.001),
and African-American ethnicity (HR 1.22; P = 0.002)
were associated with worse overall survival, whereas pa-
tients undergoing primary tumor excision (HR 0.49;
P < 0.001), female patients (HR 0.70; P < 0.001), and
patients during later time periods (P < 0.001) hadsignificantly improved overall survival (Table 2). Simi-
lar results were obtained for the cancer-specific survival
except for African-American ethnicity (HR 1.08; P =
0.058) (Table 2).
Trend analysis
Overall survival in four different time periods is dis-
played in Fig. 6 for the entire patient cohort (panel
a), as well as for non-metastatic (panel b) and meta-
static (panel c) GIST patients. There has been a sig-
nificant improvement in overall survival over time (all
GIST: PTrend < 0.001, non-metastatic GIST: PTrend =
0.001, and metastatic GIST: PTrend = 0.013). The over-
all three-year survival for all GIST patients increased
from 57.4 % (95 % CI: 48.3 to 68.2 %) in 1998 to
82.7 % (95 % CI: 79.1 to 86.3 %) in 2008. For non-
metastatic GIST, the overall three-year survival in-
creased from 68.5 % (95 % CI: 58.8 to 79.8 %) in
1998 to 88.6 % (95 % CI: 85.3 to 92.0 %) in 2008 and
for metastatic GIST from 15.0 % (95 % CI: 5.3 to
42.6 %) in 1998 to 54.7 % (95 % CI: 44.4 to 67.3 %)
in 2008. The annual percent change in three-year
overall survival from 1999 to 2008 in all GIST pa-
tients was 11.9, 11.1, 0.6, 1.4, 1.9, 1.6, 4.9,−1.4,−0.1,
and 4.1 %. In accordance with the hazard ratios and
their confidence intervals for the year of diagnosis in
the multivariable analysis (Table 2), most of the in-
crease in the survival occurred in all sub-groups dur-
ing the time before 2002. This is further depicted in
panel d additionally demonstrating extrapolated esti-
mates for the overall survival after 2008.
Figure 7 displays the Kaplan-Meier curves for cancer-
specific survival for all patients (panel a), for non-
metastatic (panel b) and metastatic (panel c) GIST pa-
tients for the same time intervals. The cancer-specific
survival significantly improved over time (all GIST:
PTrend < 0.001, non-metastatic GIST: PTrend = 0.001, and
metastatic GIST: PTrend = 0.013). The three-year cancer-
specific survival increased from 62.5 % (95 % CI: 53.4 to
73.2 %) in 1998 to 87.1 % (95 % CI: 83.9 to 90.3 %) in
2008 for all GIST patients, from 75.3 % (95 % CI: 66.1 to
85.9 %) in 1998 to 92.2 % (95 % CI: 89.4 to 95.1 %) in
2008 in non-metastatic GIST and from 15.0 % (95 % CI:
5.3 to 42.6 %) in 1998 to 61.9 % (95 % CI: 51.4 to
74.5 %) in 2008 for metastatic GIST patients. The annual
percent change for the three-year cancer-specific sur-
vival from 1999 to 2008 in the entire cohort was 16.1,
6.5, 1.5,−0.8, 3.9, 1.1, 2.4,−2.0, 1.3, and 2.4 %. Hence, the
improvement in cancer-specific survival occurred mainly
before 2002.
Discussion
This is the first population-based trend analysis of GIST
patients over an 11-year time period. The present study
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Fig. 2 Univariate survival analysis. The upper two plots display the Kaplan-Meier curves for overall (panel a) and cancer-specific survival (panel b)
in cM0 patients with and without lymph node metastases (P < 0.001). Panel (c) and (d) display the Kaplan-Meier curves in the overall cohort
comparing patients with non-metastatic and with metastatic GIST who did and did not undergo primary tumour surgery (P < 0.001 for all
comparisons). Panel (e) and (f) display the Kaplan-Meier curves for non-metastatic GIST patients according to different primary tumour sizes
(<5 cm vs. 5 to 9.9 cm: P = 0.360 for overall survival, all other comparisons: P < 0.001). Numbers of patients at risk are given below the x-axis
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and clinically relevant overall and cancer-specific sur-
vival increase from 1998 to 2008, both in non-metastaticGIST as well as metastatic GIST. In addition to the well-
known poor prognostic factors such as larger tumor size,
nodal or distant metastases, and older age, we found that
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Fig. 3 Size of GIST and survival in cM0 GIST patients. Panel (b) displays the size distribution of cM0 GIST patients (N = 3746). For each size
category, overall and cancer-specific survivals were computed (panel a)
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marital status are associated with worse overall and
cancer-specific survival.
The present trend analysis was based on over 5000 GIST
patients from the SEER registry. In this real-world analysis0 20 40 60 80 100
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Fig. 5 Predictive value of mitotic count and size for one year overall survival in cM0 GIST patients. On panel (a), the predictive value of mitotic
count for one year overall survival is depicted. On panel (b), the predictive value of the size of the GIST for one year overall survival
is demonstrated
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to the FDA approval of imatinib. One explanation is that
very low risk GIST may have been misclassified as leio-
myoma and hence were not included into our analysis prior
to the GIST consensus meeting of 2001 [14, 15]. Perez and
colleagues showed a significant increase in reported GIST
incidence from 1992 to 2002 based on SEER data, which is
almost certainly related to reclassification of various tumors
(e. g. leiomyoma) as GIST. [16] The inclusion of these tu-
mors may have falsely increased the incidence and survival
of GIST patients [17]. In the early years of our SEER ana-
lysis, the pivotal role of CD117 immunostaining was not
systematically performed as previously pointed out by Tran
and colleagues [18]. Hence, the incidence of GIST patients
reported in SEER may be lower compared to studies, for
which CD 117 staining was mandatory. Another explan-
ation of the survival increase seen in the metastatic and
non-metastatic group in the present analysis is stage migra-
tion. Indeed, PET scanning became a popular tool in the
evaluation of GIST patients in the early and mid-2000’s,
potentially leading to stage migration (Will Rogers
phenomenon). Another explanation of the improved out-
comes seen in the present investigation may the introduc-
tion of imatinib and other tyrosine kinase inhibitors in
GIST treatment. There is no doubt that the advent of ima-
tinib in treating GIST represents an important step forward
in cancer care as this targeted therapy—already very suc-
cessful in patients with chronic myeloid leukemia—was
now being applied for the first time to a solid gastrointes-
tinal cancer. Over the past decade, several randomized con-
trolled trials investigating imatinib were performed
demonstrating improved outcomes in patients with com-
pletely resected [3, 4] and metastatic GIST [5, 6]. Whilethere are currently no other drugs than imatinib being used
in non-metastatic GIST, several tyrosine kinase inhibitors
have been associated with increased overall survival in pa-
tients with metastatic GIST. In addition to imatinib, which
is used as a first line treatment, sunitinib [19] and regorafe-
nib [20] have been evaluated in phase III randomized trials
and resulted in an overall (sunitinib) and progression-free
survival benefit (regorafenib) in second and third line treat-
ment. Unfortunately, the use of tyrosine kinase inhibitors is
not coded in the SEER database and hence an association
between use of these systemic treatments and improved
outcomes remains speculative.
Therefore, with more efficacious treatment options
in advanced GIST patients, it is expected that overall
and cancer-specific survival will continue to increase
in the coming years as also shown in a data extrapola-
tion in the present study (Fig. 5). In the adjuvant set-
ting, the outcomes will most likely improve as well. In
2012, the German/Scandinavian study by Joensuu and
colleagues provided compelling evidence that high-risk
GIST patients have a better progression-free and over-
all survival with three years of adjuvant imatinib com-
pared to only one year [4]. It is well known and also
clearly seen in the German/Scandinavian trial that
most recurrences occur within the first 12–24 months
after stopping imatinib. Currently large randomized
studies are undertaken to prove the hypothesis that
5 years of adjuvant imatinib treatment is superior to
three years in the high-risk GIST subset. Selected pa-
tients with high-risk features (e. g. gastric GIST with
very high mitotic count or non-gastric GIST with high
mitotic count) may even benefit from life-long adju-
vant imatinib treatment. However, this remains to be
Table 2 Univariable and multivariable analysis of overall and cancer-specific survival
Overall survival Cancer-specific survival
Covariates Unadjusted a Cox regression, full model b Unadjusted a Cox regression, full model b
HR (95 % CI) p c) HR (95 % CI) p c) HR (95 % CI) p c) HR (95 % CI) p c)
Location Stomach Reference <0.001 Reference 0.002 Reference <0.001 Reference <0.001
Small intestine 0.87 (0.78–0.97) 0.98 (0.87–1.10) 0.90 (0.78–1.03) 0.96 (0.83–1.11)
Other 1.31 (1.13–1.53) 1.30 (1.12–1.52) 1.54 (1.30–1.84) 1.46 (1.22–1.74)
Size <5 cm Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
5 cm–9.9 cm 1.13 (0.97–1.32) 1.04 (0.89–1.21) 1.52 (1.23–1.89) 1.38 (1.12–1.72)
10 cm+ 1.94 (1.68–2.25) 1.63 (1.40–1.89) 3.15 (2.58–3.85) 2.52 (2.05–3.08)
Unknown 2.36 (2.01–2.78) 1.49 (1.25–1.78) 3.72 (2.99–4.62) 2.00 (1.58–2.52)
Metastatic disease M0 Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
M1 2.84 (2.56–3.16) 2.03 (1.80–2.28) 3.69 (3.26–4.17) 2.42 (2.11–2.78)
N stage N− Reference <0.001 Reference 0.001 Reference <0.001 Reference 0.001
N+ 2.28 (1.89–2.74) 1.47 (1.21–1.79) 2.73 (2.20–3.38) 1.55 (1.24–1.93)
NX 1.83 (1.63–2.05) 1.09 (0.96–1.24) 2.12 (1.85–2.42) 1.16 (1.00–1.36)
Surgery of the No surgery primary Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
primary Surgery primary 0.33 (0.29–0.36) 0.49 (0.43–0.56) 0.27 (0.24–0.31) 0.44 (0.38–0.52)
Unknown 0.87 (0.36–2.09) 1.36 (0.56–3.31) 0.90 (0.34–2.42) 1.36 (0.50–3.67)
Year 1998 to 2002 Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
2003 to 2005 0.79 (0.70–0.90) 0.76 (0.67–0.86) 0.76 (0.66–0.88) 0.73 (0.63–0.85)
2006 to 2008 0.67 (0.58–0.77) 0.61 (0.53–0.71) 0.66 (0.56–0.79) 0.63 (0.53–0.75)
2009 to 2011 0.63 (0.53–0.76) 0.62 (0.51–0.75) 0.55 (0.44–0.69) 0.55 (0.44–0.70)
Gender Male Reference <0.001 Reference <0.001 Reference 0.001 Reference <0.001
Female 0.79 (0.72–0.88) 0.70 (0.63–0.78) 0.81 (0.72–0.92) 0.77 (0.68–0.88)
Age <50 Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
50–64 1.27 (1.08–1.50) 1.40 (1.19–1.66) 1.00 (0.83–1.19) 1.11 (0.92–1.33)
65–79 2.25 (1.92–2.63) 2.64 (2.25–3.10) 1.54 (1.29–1.83) 1.83 (1.53–2.18)
80+ 4.92 (4.15–5.83) 5.64 (4.70–6.76) 2.91 (2.39–3.55) 3.19 (2.58–3.95)
Ethnicity Caucasian Reference 0.001 Reference 0.002 Reference 0.013 Reference 0.058
African-American 1.19 (1.06–1.35) 1.22 (1.07–1.39) 1.15 (0.99–1.34) 1.08 (0.92–1.27)
Other/Unknown 0.86 (0.74–1.01) 0.88 (0.76–1.03) 0.82 (0.68–1.00) 0.83 (0.68–1.00)
Marital status Married Reference <0.001 Reference <0.001 Reference <0.001 Reference <0.001
Single 1.18 (1.03–1.36) 1.38 (1.19–1.59) 1.29 (1.10–1.53) 1.40 (1.18–1.66)
Other/Unknown 1.48 (1.32–1.66) 1.19 (1.05–1.35) 1.44 (1.25–1.65) 1.22 (1.05–1.42)
Hazard ratios (HR) with 95 % confidence intervals
aunivariate Cox regression analysis
bmultivariable Cox regression analysis full model including all covariates depicted in the table rows on the left
clikelihood ratio tests
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well as large cohort studies.
Both size and mitotic rate—the two best-known risk
factors for recurrence—were evaluated in receiver oper-
ating curves in the present study. We identified a cut-off
value of 8 cm and a mitotic rate of 5 per 50 high power
fields (HPF) to be most predictive for cancer-specificsurvival. While the 5 mitosis per 50 HPF is a largely
used cut-off value to risk stratify GISTs [21], a size cut-
off value for worse prognosis set at 5 cm may be overly
pessimistic (Fig. 4). Indeed, in an investigation by Woo-
dall et al., which analysed GIST tumours based on SEER
data from 1974 through 2004, a size cut-off of 7 cm was
identified as an independent poor prognostic factor [22].
Fig. 6 Trends in overall survival. Panel (a) to C display Kaplan-Meier curves for overall survival for all GIST (a), non-metastatic (b) and metastatic
GIST (c) in four time intervals. The last interval from 2009 onwards is limited to two years of follow-up. Panel (d) displays the observed annual
overall survival rates from 1998 to 2008 and the extrapolated survival rates for 2009 to 2011
Güller et al. BMC Cancer  (2015) 15:557 Page 9 of 11Moreover, in both univariate and multivariable analyses,
a GIST size above 10 cm was associated with worse
cancer-specific and overall survival while patients with
GIST size between 5–10 cm had similar outcomes com-
pared to those with a size of 5 cm and below. There is no
doubt that a risk categorization of continuous biological
variables such as size and mitotic rate is problematic. In
this regard, prognostic contour maps as described by
Joensuu et al. are helpful in assessing the risk of recur-
rence in GIST patients [23].
In the present analysis, patients with small bowel GIST
had no worse overall and cancer-specific survival com-
pared to patients with gastric GIST. This is opposed to
other studies [24]. It is unclear why such a discrepancy
occurs, however, may be due to different time periods in
which the patients were enrolled in our study compared
to the one by Gold and colleagues [24].
We would like to acknowledge the limitations of this
study. The main drawback of this analysis is the lack of
information on tyrosine kinase inhibitors used, data
that cannot be ascertained in the SEER registry. Simi-
larly, information about comorbidities, performancestatus, and information on site and number of metasta-
ses are not available in the SEER database. In addition,
there is a relevant number of missing values for certain
parameters e. g. mitotic rate, which was only systemat-
ically collected in the SEER database starting 2010.
Despite these limitations, the present study has a var-
iety of strengths. First, the population-based nature of
the registry mirrors the real-world outcomes for GIST
patients and is associated with a high degree of
generalizability. It is key to evaluate to which extend
advances in often highly selected patients in random-
ized controlled trials have translated into the overall
patient population. Second, our study reports overall
and cancer-specific survival data on a 11-years time
period with extrapolation to a 14-years period. Third,
the large sample size is associated with a high degree of
power.
Conclusion
In conclusion, larger tumor size, location other than
stomach or small bowel, nodal or distant metastases,
older age, earlier time point of diagnosis, male gender
Fig. 7 Trends in cancer-specific survival. Panel (a) to (c) display Kaplan-Meier curves for cancer-specific survival for all GIST (a), non-metastatic
(b) and metastatic GIST (c) in four time intervals. The last interval from 2009 onwards is limited to two years of follow-up. Panel (d) displays the
observed annual cancer-specific survival rates from 1998 to 2008 and the extrapolated survival rates for 2009 to 2011
Güller et al. BMC Cancer  (2015) 15:557 Page 10 of 11and single marital status are associated with significantly
worse overall and cancer-specific survival. There has
been a substantial increase in overall and cancer-specific
survival from 1998 to 2008. It is anticipated that the
current availability of different tyrosine kinase inhibitors
in the advanced setting and better selection of high-risk
patients benefitting from long-term adjuvant imatinib
will continue to lead to a further improvement in patient
outcomes.
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